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T he thalassemias are the most common human monogenic dis-eases.1 These inherited disorders of hemoglobin synthesis are characterized by a reduced production of globin chains of hemoglobin.2 Worldwide, the 
most important forms are the α- and β-thalassemias, which affect production of 
the α-globin and β-globin chains, respectively. Although β-thalassemia is the more 
clinically significant form,3 α-thalassemia occurs at a high frequency across the 
tropical belt, almost reaching fixation (a term in population genetics denoting that 
a mutant allele of a particular gene has become the only allele expressed in the 
population — i.e., that it has reached a frequency of 100%) in parts of southern 
Asia. It has been estimated that about 5% of the population worldwide carry an 
α-thalassemia variant.4-7
There is growing evidence that the health and economic burden of the thalas-
semias is increasing owing to population growth and epidemiologic transition in 
tropical regions8 and to human migrations in other parts of the world.9-12 (Epide-
miologic transition refers to a change in patterns of population age distributions, 
mortality, fertility, life expectancy, and causes of death, usually reflected by a shift 
from deaths caused by infectious diseases to deaths caused by chronic and degen-
erative diseases.) Population growth leads to an absolute increase in the number 
of births affected. Epidemiologic transition improves the diagnosis of hemoglo-
binopathies and the survival of affected persons, increasing the incidence of the 
disorders. Population migrations, although not always leading to an increase in 
global prevalence, contribute to the spreading of hemoglobinopathies and thus 
increase the number of countries that require the implementation of specific inter-
ventions to educate larger populations, diagnose the disorders, and counsel affected 
patients and that must account for these interventions in their health budget.
Although our epidemiologic knowledge of the distribution, prevalence, genetic 
diversity, and health burden of both α-thalassemia and β-thalassemia is limited 
and largely outdated, gaps are more pronounced in the case of α-thalassemia. This 
relative lack of a strong evidence base is likely to contribute to the low priority of 
this disorder on many public health agendas. Existing reviews focus mainly on 
molecular and clinical aspects of α-thalassemia.13-16 Our aim in this article is to 
provide a contemporary summary of our epidemiologic knowledge of α-thalassemia 
and to discuss the various challenges faced by the medical and public health com-
munities in light of recent findings on the severity and genetics of this inherited 
disorder.
CLINIC A L R ELE VA NCE
Normal adult hemoglobin consists of pairs of α and β chains (α2β2), and fetal he-
moglobin has two α chains and two γ chains (α2γ2). The genes for the α chains and 
γ chains are duplicated (αα/αα, γγ/γγ), whereas the β chains are encoded by a 
single gene locus (β/β). In the fetus, defective production of α chains is reflected 
by the presence of excess γ chains, which form γ4 tetramers, called hemoglobin 
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Bart’s; in adults, excess β chains form β4 tetra-
mers, called hemoglobin H (HbH). Because of 
their very high oxygen affinity, both tetramers 
cannot transport oxygen, and, in the case of HbH, 
its instability leads to the production of inclusion 
bodies in the red cells and a variable degree of 
hemolytic anemia.
More than 100 genetic forms of α-thalassemia 
have thus far been identified,17 with phenotypes 
ranging from asymptomatic to lethal. Despite 
this complexity, the severity of this disorder is 
usually well correlated with the number of non-
functional copies of the α-globin genes (Fig. 1). 
On the basis of the numbers of α-globin genes 
lost by deletion or totally or partially inactivated 
by point mutations, the α-thalassemias are clas-
sified into two main subgroups: α+-thalassemia 
(formerly called α-thalassemia 2), in which one 
pair of the genes is deleted or inactivated by a 
point mutation (−α/αα or ααND/αα, with ND de-
noting nondeletion), and α0-thalassemia (former-
ly called α-thalassemia 1), in which both pairs of 
α-globin genes on the same chromosome are 
deleted (−−/αα).
Clinically relevant forms of α-thalassemia 
usually involve α0-thalassemia, either coinherited 
with α+-thalassemia (−α/−− or ααND/−−) and re-
sulting in HbH disease or inherited from both 
parents and resulting in hemoglobin Bart’s hy-
drops fetalis (−−/−−), which is lethal in utero or 
soon after birth. Affected embryos succumb to 
severe hypoxia either early in gestation (e.g., in 
the case of −−FIL/−−FIL [with FIL referring to a 
deletion that causes α0-thalassemia and that is 
prevalent among Filipinos]) or during the third 
trimester (e.g., in the case of −−SEA/−−SEA [with 
SEA referring to a deletion that causes α0-thalas-
semia and that is prevalent among persons from 
Southeast Asia]).18
A few children with hemoglobin Bart’s hydrops 
fetalis who received an intrauterine transfusion 
or a transfusion immediately after delivery have 
survived to 5 years of age. These children require 
regular transfusions and, when appropriate, iron-
chelation therapy; they usually have serious clini-
cal complications, congenital anomalies, and 
delays in cognitive and motor functions.9 The 
hemoglobin Bart’s hydrops fetalis syndrome is 
often accompanied by a variety of congenital 
malformations and maternal complications, in-
cluding severe anemia of pregnancy, preeclamp-
sia, polyhydramnios, and extreme difficulty in 
delivery of both the fetus and the hugely en-
larged placenta.18,19 Although these complica-
tions have been well documented, there are very 
limited data regarding the frequency of maternal 
deaths, particularly in the developing countries 
in which this condition is so common.
HbH disease is often considered to be a rela-
tively mild disorder. Studies have nevertheless 
highlighted clinically severe phenotypes, notably 
in nondeletional variants of the disease.20-22 In 
fact, HbH disease is characterized by a wide 
range of phenotypic characteristics. The form 
that results from deletions (−α/−−) usually fol-
lows a relatively mild course, with moderate 
anemia and splenomegaly. Aside from episodes 
of intercurrent infection, this form of HbH dis-
ease does not require blood transfusions. How-
ever, the variety that results from the interac-
tions of a nondeletional α-globin gene mutation 
together with α0-thalassemia (ααND/−−) follows 
a much more severe course. This is particularly 
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Figure 1. Phenotype–Genotype Relationship in α-Thalassemia.
In rare cases, hemoglobin H (HbH) disease or hemoglobin Bart’s hydrops 
fetalis can result from homozygosity for nondeletional forms of α-thalas-
semia. Although HbH disease is usually symptomatic, some patients, par-
ticularly those with deletional variants of α-thalassemia, are asymptomatic. 
Furthermore, three α-globin gene deletions involving severe nondeletional 
mutations (e.g., hemoglobin Constant Spring) can also cause the hemoglo-
bin Bart’s hydrops fetalis syndrome. With regard to the lethality of hemo-
globin Bart’s hydrops fetalis, four α-globin gene deletions with persistence 
of an intact embryonic ζ-globin gene — for example, –(α)20.5 in the Medi-
terranean area — may be associated with neonatal survival.
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true when the nondeletional mutation is the 
α-globin chain termination mutant hemoglobin 
Constant Spring, which is very common in many 
Asian countries. Nondeletional forms of HbH 
disease are characterized by severe anemia, of-
ten occurring from early life, and are associated 
with increasing splenomegaly, iron loading, and 
a variety of other clinical complications, includ-
ing infections, leg ulcers, gallstones, and folic 
acid deficiency. Although splenectomy is often 
indicated, nondeletional HbH disease is associ-
ated with a particularly high rate of thrombotic 
complications. This observation makes the deci-
sion between splenectomy and lifelong transfu-
sion extremely difficult.
Milder variants of α-thalassemia act as genetic 
modifiers of other inherited conditions, as illus-
trated by epistatic interactions (when one gene 
influences another) between α-thalassemia and 
β-thalassemia23 or between α-thalassemia and 
hemoglobin S (sickle hemoglobin).24 Triplica-
tions and quadruplications of the α-globin gene 
have been frequently observed in many popula-
tions, and these can interact with β-thalas semia 
variants to produce more severe phenotypes.25,26
Finally, there are two syndromes in which 
α-thalassemia is associated with mental retarda-
tion (ATR syndromes).14,27 Details regarding 
these syndromes are provided in the Supplemen-
tary Appendix, available with the full text of this 
article at NEJM.org.
DI AGNOSIS
Prenatal diagnosis is required to identify fetuses 
affected by hemoglobin Bart’s hydrops fetalis 
and to reduce the risks to the mothers. The deci-
sion to consider such a diagnosis usually follows 
the finding of hypochromic microcytic red cells 
in both parents, in association with a normal he-
moglobin A2 level; this combination would rule 
out β-thalassemia, which usually involves an ele-
vated hemoglobin A2 level. Iron deficiency also 
has to be ruled out. When facilities for rapid 
DNA diagnosis are available, the hematologic ex-
amination is followed by confirmation of the 
presence of α0-thalassemia in the parents. The 
fetal diagnosis is usually made early in pregnancy 
by means of chorionic-villus sampling, although 
fetal anemia may also be diagnosed later during 
gestation by quantitation of the peak systolic 
velocity in the middle cerebral artery.28 Various 
alternative methods of preimplantation and pre-
conception genetic diagnosis or prenatal diagno-
sis — for example, analysis of maternal blood for 
fetal DNA and identification of fetal cells in ma-
ternal blood by staining with antibodies against 
globin chains — are still at relatively early stages 
of study. Meanwhile, attempts at intrauterine and 
postnatal therapy are associated with numerous 
ethical challenges.29
The homozygous state of α+-thalassemia and 
the heterozygous state of α0-thalassemia (grouped 
under the term “α-thalassemia minor”) are asso-
ciated with a substantial reduction in the mean 
corpuscular volume and mean corpuscular hemo-
globin. In α+-thalassemia heterozygotes, the mean 
corpuscular volume and mean corpuscular hemo-
globin are usually reduced, but there is a small 
overlap with normal values. Milder forms of 
α-thalassemia are often misdiagnosed as iron 
deficiency, although the exact frequency of mis-
diagnosis is unknown.30 Ultimately, the diagno-
sis of a particular variant of α-thalassemia can 
be confirmed only at the DNA level.
In the pregenomic era, the frequency of 
α-thalassemia was assessed according to the 
presence of hemoglobin Bart’s in cord blood. 
The detection of hemoglobin Bart’s in newborns 
indicates that one or more of the four α-globin 
genes are dysfunctional, causing α-thalassemia. 
Although the level of hemoglobin Bart’s at birth 
was initially thought to be a sensitive indicator 
of the presence of α-thalassemia and to correlate 
well with its severity, later DNA-based studies 
showed that this diagnostic method fails to de-
tect a substantial number of α+-thalassemia 
heterozygotes and therefore underestimates the 
frequency of α-thalassemia.18 It is now well es-
tablished that diagnosis of α-thalassemia on the 
basis of hemoglobin Bart’s alone is not reliable 
and does not allow identification of the geno-
types. This method is nevertheless still widely 
used in low- and middle-income countries be-
cause it is relatively straightforward and much 
cheaper than DNA analysis.
GEO GR A PHIC DIS TR IBU TION
Evidence that α-thalassemia is highly protective 
against severe malaria is well established.5 As a 
result of this selective advantage, heterozygous 
α-thalassemia has reached high frequencies 
throughout all tropical and subtropical regions, 
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including most of Southeast Asia, the Mediter-
ranean area, the Indian subcontinent, the Middle 
East, and Africa. Common α0-thalassemia vari-
ants, predominantly the −−SEA mutation in South-
east Asia and the −−MED mutation in the Mediterra-
nean, have reached frequencies of approximately 
5%. Although there are at least seven deletional 
forms of α+-thalassemia, as shown in Figure 2A, 
the −α3.7 variants are the most common. Frequen-
cies of 70% and up to 90% have been reported in 
Melanesia5 and in parts of Nepal,7 respectively. 
The mechanisms by which such frequencies close 
to fixation have been reached require further in-
vestigation.31,32 In addition to studies that have 
revealed negative epistasis between α+-thalas-
semia and the sickle cell trait, resulting in a re-
duced level of malaria protection when the two 
are coinherited,24 mathematical models have sug-
gested that the frequency of α+-thalassemia 
might be constrained by the presence of the sick-
le cell gene in Africa and the Mediterranean.33,34
In conjunction with large-scale global popu-
lation movements in recent decades, α-thalas-
semia has spread to many other parts of the 
world, including northern Europe and North 
America. This phenomenon is best illustrated by 
the implementation in 1998 of a universal screen-
ing program for α-thalassemia in California. 
After the immigration of large numbers of peo-
ple from the Philippines and other Southeast 
Asian countries, the incidence of α-thalassemia 
syndromes in California between January 1998 
and June 2006 was 11.1 cases per 100,000 persons 
screened, with 406 cases of HbH disease and 
5 cases of hemoglobin Bart’s hydrops fetalis.15 
Because of the high frequency of α+-thalassemia 
variants worldwide (Fig. 2A), it is likely that, 
with admixture of local populations and immi-
grants, such spread will increase the incidence 
of HbH disease (Fig. 2C), in addition to creating 
a health burden in a growing number of coun-
tries or regions.
Various population surveys of hemoglobinopa-
thies have revealed remarkable geographic hetero-
geneities in the prevalence of these disorders.35 
In the mid-1980s, Flint and colleagues observed 
frequencies of α+-thalassemia ranging from 6 to 
68% across Melanesian islands.5 Similar hetero-
geneities were later described in Vanuatu.36 In a 
recent micro-mapping survey conducted across 
Sri Lanka, the prevalence of α-thalassemia ranged 
from 2 to 20% (Weatherall DJ, et al.: unpub-
lished data). This variability is likely to be the 
result of a series of complex environmental fac-
tors, including the rate of malaria transmission. 
A better understanding of these interactions will 
help considerably in refining estimates of popu-
lations affected in tropical regions (Fig. 2B and 
2C) and in developing policies for the diagnosis 
and management of α-thalassemia on the basis 
of characteristics of the local population. A pre-
cise quantification of the populations at risk for 
α-thalassemia syndromes at the national, re-
gional, and global levels is necessary to define 
current and future resources required to provide 
accurate prenatal diagnosis of α-thalassemia 
variants, emergency management of pregnancies 
involving hemoglobin Bart’s hydrops fetalis and 
associated maternal complications, and long-
term management of HbH disease.
SCR EENING
The primary objectives of thalassemia screening 
programs are to determine the frequency of the 
different genetic variants observed in the com-
munities and to identify and inform couples who 
are at risk, particularly for severe forms of the 
disease occurring in areas of high frequency. 
Screening for α-thalassemia is especially helpful 
in preventing severe maternal complications in 
the case of hemoglobin Bart’s hydrops fetalis and 
in providing accurate diagnosis in cases in which 
α-thalassemia is coinherited with hemoglobin S 
or β-thalassemia or in cases in which iron defi-
ciency is detected. Most α-thalassemia screening 
surveys are conducted as part of a β-thalassemia 
prevention program and are therefore not ade-
quate to determine population frequencies of 
α-thalassemia. The benefits of population screen-
ing should be carefully considered in any popu-
lation in which α-thalassemia variants are prev-
alent and cases of unexplained microcytic 
hypochromic anemia in the absence of iron defi-
ciency are observed.18 Major screening efforts 
that have been implemented in various countries 
and their main outcomes are summarized in the 
Supplementary Appendix.
HE A LTH A ND ECONOMIC BUR DEN
Early studies of the global burden of hemoglobin 
disorders that evaluated the frequency of the dis-
orders and the number of disability-adjusted life-
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years (DALYs) associated with them were limited 
by a lack of data on α-thalassemia, particularly 
with regard to hemoglobin Bart’s hydrops fetalis 
and its burden through stillbirths or deaths 
shortly after delivery.37 The World Health Orga-
nization (WHO) does not collect data on still-
births, and the only data that were available pro-
vided an estimate of 1250 pregnancies involving 
homozygous α0-thalassemia per year in Thailand, 
a figure that amounts to 37,242 DALYs. In com-
parison, homozygous β-thalassemia and hemo-
globin E β-thalassemia were estimated to result 
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in a total of 53,600 DALYs in Thailand, on the 
basis of a life expectancy of 10 years and 30 
years, respectively. These are likely to be under-
estimates because the mother’s disability was 
accounted for only in the last trimester of preg-
nancy, without consideration of postnatal com-
plications that can result in death, and because 
estimates were not calculated for HbH disease, 
since data were collected before it was realized 
that a particularly severe form of HbH disease 
occurs in many Asian countries. Information on 
the incidence of α-thalassemia was insufficient 
to permit calculation of the regional and global 
burden of disease.37 Global estimations of the 
number of DALYs resulting from hemoglobinop-
athies have recently been reported in the Global 
Burden of Disease Study 2010, although no ac-
curate data on the various subtypes of thalas-
semia have yet been added to this project.38,39
To our knowledge, there has been only one 
study to date that has investigated the cost–bene-
fit ratio of an α-thalassemia prevention program, 
whether established on its own or as part of a 
broad program for all the thalassemias or for 
genetic conditions (e.g., phenylketonuria) in gen-
eral. The study, conducted in Hong Kong, con-
cluded that universal prenatal screening for the 
α- and β-thalassemias with the use of DNA 
testing was cost-effective, although no published 
data on the cost of managing a pregnancy af-
fected by hemoglobin Bart’s hydrops fetalis were 
available.28 Whether these results apply to coun-
tries with larger populations and lower incomes 
than those in Hong Kong needs to be carefully 
investigated.40 The benefits of accurate diagno-
sis of iron deficiency and other hemoglobinopa-
thies — hemoglobin S and β-thalassemia in 
particular — should also be considered. Cost–
benefit analyses of β-thalassemia prevention pro-
grams in Quebec,41 Iran,42 Israel,43,44 and the 
United Kingdom45 have generally confirmed the 
overall benefits of such programs (i.e., the costs 
of prevention were lower than the costs of treat-
ment), but the studies did not include α-thalas-
semia. In low- and middle-income countries, the 
implementation of such programs could benefit 
from existing infrastructures (e.g., ongoing 
screening programs for phenylketonuria or glu-
cose-6-phosphate dehydrogenase deficiency) or 
could result in an overall improvement in access 
to health care for local communities.46
M A NAGEMEN T
A detailed knowledge of the prevalence of α-thal-
assemia (including carrier status) and of its ge-
netic diversity is essential to define policies aimed 
at reducing the long-term health burden of hemo-
globinopathies, allowing for precise diagnosis 
(and therefore avoiding inaccurate and expensive 
investigations), establishing the real cause of mi-
crocytosis, providing adequate genetic counseling, 
and allocating resources to address the emergen-
cy and long-term needs of patients and their rela-
tives in a cost-effective manner. To achieve these 
goals, the medical community faces several im-
portant challenges, summarized in Table 1.
Most couples at risk for conceiving fetuses 
with hemoglobin Bart’s hydrops fetalis are not 
currently identified. It is therefore highly likely 
that current estimates represent large underesti-
mates of stillbirths caused by this disorder.4 In 
the absence of specific treatments and a clear 
understanding of the underlying mechanisms re-
sponsible for the wide range of congenital ab-
normalities associated with this lethal disorder, 
screening and early prenatal diagnosis represent 
the only options to identify pregnancies at risk 
and to prevent severe maternal complications. 
Although termination of affected pregnancies is 
Figure 2 (facing page). Geographic Distribution of 
α-Thalassemia, Hemoglobin Bart’s Hydrops Fetalis,  
and HbH Disease.
Panel A shows a map of our current knowledge of the 
distribution, prevalence, and genetic diversity of α-thalas-
semia globally. Only the most common variants for  
α+-thalassemia (−α3.7and −α4.2) and α0-thalassemia  
(−−MED and −−SEA) are shown for each region. The vari-
ants that appear in parentheses in Panel A are those 
for which the data used to make this map are limited. 
The information in Panel A is based on data from 
Weatherall and Clegg.18 Panel B shows current estimates 
of the annual number of births affected by hemoglobin 
Bart’s hydrops fetalis (−−/−−), and Panel C shows births 
affected by HbH disease (−α/−−). No difference is indi-
cated between countries in which the disorder has not 
been reported and those for which no data are available. 
The maps in Panels B and C highlight various inconsis-
tencies (indicated by a question mark) in current esti-
mates, particularly in the Mediterranean area and, with 
regard to HbH disease, in India and western Europe. 
These maps also reveal the need for subnational esti-
mates, as in the United States and China. The informa-
tion in Panels B and C is based on data from Modell 
and Darlison.4
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usually recommended owing to the increased risk 
of severe maternal and fetal complications and 
the psychological effects on families, cultural and 
religious backgrounds need to be carefully taken 
into account when counseling couples at risk, 
both in communities in which α-thalassemia has 
traditionally been prevalent and in those in which 
it has recently been introduced through migra-
tion.18,47 A correct diagnosis early in pregnancy is 
essential to avoid severe medical complications 
and psychological trauma. Such a diagnosis can 
be made reliably with relatively low costs provided 
that pregnant women receive regular follow-up 
care from medical staff familiar with this syn-
drome.
Recent progress in DNA testing has revealed 
a greater phenotypic diversity in HbH disease 
than previously thought.20,22 As noted above, non-
deletional variants are usually more severe than 
deletional variants. It is therefore crucial to con-
duct DNA analyses to identify the underlying 
genetic variant responsible for this disorder. Gap–
polymerase chain reaction (PCR) and multiplex-
PCR assays allow easy screening for a range of 
common variants,48 but such methods remain 
costly and are not widely used in low- and middle-
income countries. With DNA testing methods 
becoming more and more affordable, it is likely 
that this will become a regular part of the ser-
vices available for the control and management 
of thalassemias, particularly in Asian countries.49 
As our knowledge of the phenotype–genotype 
relationship in HbH disease improves, correct 
genotype identification will become essential to 
inform parents about reproductive risks during 
genetic counseling and to provide appropriate 
care to affected patients.
With increasing population movements, the 
diversity of combinations of α-thalassemia 
variants or coinherited hemoglobinopathies will 
continue to increase. Although it is difficult to 
predict the exact phenotype of such new com-
binations, a detailed knowledge of the current 
distribution of genetic variants will at least help 
in defining diagnostic procedures and in assess-
ing the potential risks. Collaborations between 
“source” areas (those with a high prevalence of 
α-thalassemia and substantial emigration) and 
“sink” areas (those with substantial immigra-
tion from source areas), as have developed be-
tween the Philippines and California and between 
Sri Lanka and the United Kingdom, certainly 
represent beneficial models for both sides and 
should be replicated more widely.50,51
The health burden of α+-thalassemia is cur-
rently not known. Although α+-thalassemia vari-
ants alone do not represent a direct clinical prob-
lem, they are probably the most common genetic 
disorders in the world, and they represent impor-
tant genetic modifiers for a range of other con-
ditions, including malaria, sickle cell disorders, 
β-thalassemia, and iron deficiency. A better 
understanding of these interactions is crucial to 
provide appropriate diagnosis and treatment for 
affected patients but is relevant only if interven-
tions resulting from our improved understand-
ing are implemented in all areas in which these 
interactions are occurring. For example, whether 
epistatic interactions between the sickle cell trait 
and α+-thalassemia that have been observed in 
Kenya24 are also occurring in Indian populations 
is currently not known.
Because of the remarkable geographic hetero-
geneities in the prevalence of α-thalassemia, inter-
ventions have to be tailored to the specific charac-
teristics of the local population (e.g., prevalence of 
the disorder in the population, ethnic makeup, and 
consanguinity) and the local health care sys-
tem.35,52 A better understanding of the relationship 
among the prevalence of α-thalas semia variants, 
environmental factors, and infections, combined 
with modern analytic and modeling methods, 
would support more refined estimates of affected 
populations. Such knowledge would also help 
Table 1. Main Challenges Associated with the Increasing Health Burden  
of α-Thalassemia and Recommendations for Addressing Them.
Challenge Recommendation
Prevention of hemoglobin Bart’s  
hydrops fetalis
Education, screening and counseling; 
 prevention of maternal complications
Accurate diagnosis of hemoglobin  
H disease
Affordable DNA-screening methods
Increase in international migration International collaborations
Geographic heterogeneities Micro-mapping studies
Better understanding of phenotype–
genotype interactions and of  
the role of environmental and 
 genetic modifiers
Theoretical epidemiologic modeling 
alongside clinical studies
Need for reliable population esti-
mates of affected persons
Population surveys and data sharing
Sustainable allocation of resources 
for the management and control 
of thalassemias
Greater awareness and more cost– 
benefit analyses
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in the development of stratified prevention pro-
grams that focus, for example, on regions in which 
α0-thalassemia variants are the most prevalent.
CONCLUSIONS
The α-thalassemias represent a global health 
problem with a growing burden.11 A refined 
knowledge of the molecular basis of α-thalas-
semia53,54 will be fully relevant from a public 
health perspective only if it is complemented by 
detailed epidemiologic data. To ensure appropri-
ate care of patients and the sustainability of 
health care systems, more effort must be put into 
obtaining evidence-based estimates of affected 
populations, providing resources for the preven-
tion, control, and management of the thalas-
semias, and performing cost-effectiveness analy-
ses.28 Such goals will be achieved only through a 
concerted effort by the research and medical com-
munities and the support of international fund-
ing agencies to collect and share epidemiologic 
data.55 The recent inclusion of hemoglobinopa-
thies in the Global Burden of Disease Study56 and 
the assessment of the burden of α-thalassemia in 
terms of DALYs will be meaningful only if con-
temporary and reliable data are available.
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